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hormones by means ofdirect binding experiments with radiolabeled ligands. Existence of specific binding sites for several hormones has been demonstrated not only in specific target tissues, but also in peripheral tissue, where actions of these hormones are unknown at a molecular level. Molecular alterations of human target tissue, which could be associated with the pathogenesis of certain diseases, can therefore be analyzed by comparing hormone action on target tissue in vivo with that ofreadily accessible peripheral tissue in vitro. For example, decreased insulin binding to adipocytes was shown to correlate with decreased binding to circulating monocytes from obese subjects (1) . Thus, an estimation of direct insulin binding to monocytes in vitro could be indicative of insulin action in vivo (2) .
It appears to be a valid generalization that the sensitivity of tissues varies inversely with the availability of hormone under different pathophysiological situations of the organism, and that often the altered sensitivity of tissues to exogenously administered hormone may be directly correlated to the receptor content of the tissues. For instance, insulin binding studies on human peripheral leukocytes have been used for the detection of insulin receptor defects in human insulin-resistant states (3, 4) . Recently Williams et al. (5) reported the first successful application of direct binding studies to the identification of 83-adrenergic receptors in human tissue by characterizing (-) [3H]-alprenolol receptors in the human circulating lymphocyte. The clinical implications of such receptor studies using direct binding methods have been reviewed by Lefkowitz (6) and Baxter and Funder (7) . There is evidence that receptors for both catecholamines and peptide hormones are localized on the membrane of various cell types (7) . To achieve new physiologic and biochemical information on the action of vasopressin in various clinical situations, we were interested in characterizing specific receptors for the peptide in the human circulating blood cells by using direct binding studies.
We report here the observation that the radioligand 15I-8-L-arginine vasopressin (AVP)1 is capable of binding to human mononuclear phagocytes, which may provide a useful tool for studies on abnormal receptor properties in human disease. were kept on ice. Lymphocytes, polymorphonuclear leukocytes, and erythrocytes were prepared according to the methods described by Williams et al. (5) .
METHODS
125I-AVP binding assay. For the binding assay, mononuclear phagocytes were suspended in the assay buffer containing 100 mM Hepes, 120 mM MgSO4, 15 mM Na acetate, 1 mM EDTA, and 1% bovine serum albumin, pH 8. Cells at a concentration of2 x 106 were incubated in a total volume of 1 ml with 125I-AVP and unlabeled hormone in 5-ml plastic tubes (Falcon Labware) for various time intervals at 22°C, as described in the legends to our figures and tables. For competition experiments with the structural antidiuretichormone (ADH) analogues, various concentrations ofthe compounds were added as described below. The reaction was terminated by washing of the cells (5', 900 g, 40C). The cell pellet was resuspended in 5 vol of buffer and washed twice (5', 900g, 40C) and radioactivity in the cell pellets was counted in a Packard Auto Gamma Scintillation Spectrometer (Packard Instrument Co., Inc., Downers Grove, Ill.) with efficiency of 50%. All assays were run in trlplicate.
In each experiment total binding of 125I-AVP to the cells was determined by incubating the cell preparations with the radioligand in the absence of unlabeled peptide and by measuring the amount of radioactivity retained on the cells. "Specific" binding of the radioligand was analyzed in a separate incubation by adding a 2.5-fold excess of unlabeled hormone, and was 85-95% of total '25I-AVP bound to the cells. Values obtained for total binding minus specific binding values refer to "nonspecific" binding.
For the binding studies on cells from patients, only the mononuclear cell fraction was prepared from 80-100 ml heparinized blood. These studies included three patients with the hereditary type of diabetes insipidus (one male and two females), five male patients with maturity onset diabetes mellitus, and seven male normal donors. The hereditary type of diabetes insipidus was traced through four consecutive generations. Urine volumes of the patients before therapy (8.3-13.3 liters/d) and osmolality (85-145 mosmol/kg) changed to volumes in the range of 1.5-1.6 liters/d and to an osmolality of 500-780 mosmol/kg, when the patients were treated twice a day with 0.1 mg d-DAVP.
Binding of either 125I-AVP (40 pM) or '251-insulin (33 pM); specific activity 160-180,uCi/,Lg prepared as described by Gambhir et al. (10) was determined according to DeFronzo et al. (2) . Briefly, 3 x 106 mononuclear cells (containing 2.5 x 105 mononuclear phagocytes) were incubated in a final volume of 1 ml assay buffer in the presence or absence of unlabeled hormone. The nonspecific binding of 1251-insulin was defined by the amount of 1251-insulin bound to the cell pellet in the presence of 104 ng/ml of unlabeled insulin, and was found to amount to 0.3-0.5% of the total radioactivity added to the cells obtained from normal or diabetic subjects or from patients with the hereditary type ofdiabetes insipidus. The nonspecific binding of 125I-AVP was determined in the presence of 100,000-fold excess of unlabeled peptide and was 0.3-0.7% ofthe total radioactivity added for all groups tested. The experiments were performed in duplicate.
Cyclic AMP measurements. To determine the intracellular level of cyclic AMP, accumulation measurements were performed in the presence of the phosphodiesterase inhibitor IBMX at a final concentration of 0.1 mM. Experimental treatment and processing of the cells for the cyclic AMP assay were performed as described by Higgins and David (11) , except that the cells (8 x 106/ml) were incubated in Eagle's minimal essential medium in the absence of serum for various time intervals, as described below. At the end of the assay period 1 ml of ice-cold 10% trichloroacetic acid (which contained 0.1 pmol or -2,000 cpm of [3H]cyclic AMP to measure recovery) was added to 1 ml of the cell suspension. After boiling for 5 min and addition of2 ml ethanol:30% HCl (60:1), the samples were homogenized (Polytron Kinematica, Lucerne, Switzerland) at maximum velocity for 30 s. The homogenates were centrifuged at 5,000 g for 15 min at 4°C. The pellets were solubilized in 2% sodium dodecyl sulfate and the protein content was determined according to Lowry et al. (12) by using bovine serum albumin (Sigma Chemical Co.) as a standard. The supernates were lyophilized and redissolved in sodium borate buffer (50 mM), pH 8.9, containing 0.1% gelatine.
To determine the intracellular cyclic AMP level, 100-,ul aliquots were assayed by using the cyclic AMP (1251) radioimmunoassay kit (New England Nuclear). Each sample was assayed in triplicate. The results are expressed as picomoles of cyclic AMP per milligram of protein (or -1.1 x 107 mononuclear phagocytes). Vasopressin-induced cyclic AMP accumulation was further demonstrated by product identification, as incubations of the supernates with beef heart cyclic-3',5'-phosphodiesterase (Sigma Chemical Co.) for 3 h at 300C at pH 7.5 according to the method of Butcher and Sutherland (13) decreased the measurable cyclic AMP by 95%.
To substantiate the relationship between binding of the ligand and cyclic AMP accumulation, the cells were exposed to various concentrations of either 125I-AVP, 1251-LVP, 1251-d-DAVP, or '251-oxytocin for 30 min at 37°C. After termination of the reaction by addition of 10% trichloroacetic acid, the cells were processed as described above. The supernates were analyzed for cyclic AMP after separation of the radioligands on ion-exchange columns (1-x, 200-400 mesh Bio-Rad Laboratories, Richmond Calif.) as described by Murad et al. (14) .
To determine cyclic AMP recovery, 3H-cyclic AMP (in the same amount as described above) was added to the experimental samples, which were then subjected to the column procedure. The recovery was found to be -75%. The eluted fractions containing cyclic AMP were pooled, lyophilized, resuspended in 5 ml assay buffer, and analyzed for cyclic AMP content by using the cyclic AMP Table I , mononuclear phagocytes (88% pure) bound 2.8 fmol 125I-AVP/2 x 106 cells per ml, whereas the specific binding of the radioligand to preparations of purified leukocytes (98% lymphocytes, 1.5% mononuclear phagocytes, and 0.5% polymorphonuclear leukocytes) was 0.2 fmol/2 x 106 cells. Preparations of highly purified polymorphonuclear leukocytes and erythrocytes revealed specific binding of the radiolabeled hormone between 0.2 and 0.09 fmol/2 x 106 cells per ml.
Binding of 125I-AVP to human mononuclear phagocytes. The amount of vasopressin that binds to human mononuclear phagocytes is dependent on the time of incubation (Fig. 1) . At a concentration of 40 pM 125I1 AVP, the amount of specifically bound hormone increases with time and reaches an equilibrium value of 10±0.5%/2 x 106 cells total binding within 30-40 min. Nonspecific binding under these conditions was determined in the presence of 100 pM of unlabeled peptide to be 1.5±0.12%. Thus, mononuclear phagocytes bind specifically 8.5±0.8%/2 x 106 cells.
To exclude the possibility that the radioligand binding was due to internalization by the mononuclear phagocytes, the cells were treated with cytochalasin B (10 ,gIml) to inhibit phagocytosis (15) . No significant difference was found in specific binding of 125I-AVP (40 pM) between those cells treated with and those without cytochalasin B, which indicates that the observed binding was not caused by endocytosis of the radioligand. Cell populations were isolated from blood of healthy donors as described in Methods. Cells at a density of 2 x 106/ml were incubated with 40 pM of 125I-AVP in the presence of 100 pM unlabeled hormone for 2 h at 22'C. Cells were stained with Turk's solution, and differential counts were done in triplicate for each individual experiment. Mononuclear phagocytes were stained by the nonspecific esterase method (9) . The data represent the mean of triplicate incubations of three independent experiments (+SD). As is shown in Fig. 2 To characterize the specificity of the vasopressin 300 400
receptors, the cells were incubated with 125I-AVP -f
in the presence of varying amounts of unlabeled structural analogues, and the displacement ofthe radioligand was assessed. As is illustrated in Fig. 4 related, the structural analogues should increase the level ofcyclic AMP at concentrations similar to those at which they competed for 125I-AVP binding. As is illustrated in Fig. 6 , AVP was by far the most active hormone in stimulating intracellular cyclic AMP synthesis, followed by LVP, d-DAVP, and oxytocin. The timecourse for the elevation of intracellular cyclic AMP level by AVP (500 pM) revealed a significant increase after 5 min of incubation, peaking at 15-30 min and returning to basal values at 40-120 min (Fig. 5) 4- valine, 8-D-arginine] vasopressin has a Kd value similar to AVP, and has been shown to completely inhibit the antidiuretic action of LVP in the rat system (17) . It is almost as effective in decreasing 125I-AVP binding as AVP. On the other hand, insulin, which has been reported to act on specific sites on human monocytes and erythrocytes (1, 2, 10), angiotensin II, and ACTH -all of which lack antidiuretic activity-did not interfere with radioligand binding. These observations strongly suggest specificity for hormonal binding.
Various studies have shown the existence of specific sites for certain ligands on the mononuclear phagocytes capable of affecting cyclic AMP metabolism in these cells (25) . By comparing the concentrations ofthe hormone that lead to maximal stimulation of endogenous cyclic AMP accumulation in the mononuclear phagocytes with those required for maximal specific binding, we find that the effective concentrations in both experiments are in a similar range: between 100 and 1,000 pM. The binding affinities of LVP, d-DAVP, and oxytocin paralleled the required concentrations of these agents to stimulate intracellular cyclic AMP production in mononuclear phagocytes. The observation that optimum concentrations ofvasopressin and its analogues are required to give a maximum response in intracellular levels of cyclic AMP, whereas higher concentrations of AVP were less effective, is in agreement with a report by Schwartz et al. (26) , who described a biphasic phenomenon for vasopressin-induced intracellular accumulation of cyclic AMP in epithelial cells from the collecting bovine duct of the kidney. Though various explanations for the biphasic effect of vasopressin on cyclic AMP metabolism in mononuclear phagocytes are possible (e.g., changes in coupling between receptors and adenylate cyclase, with subsequent changes in cyclic AMP synthesis in the presence of high concentrations of the hormone; or alterations in ion fluxes caused by unphysiologic concentrations of the ADH), at present we do not have a mechanical explanation for this phenomenon. Another discrepancy was seen when the effective concentration of vasopressin leading to maximum saturation of its receptors (120-170 pM) was compared with that causing maximum stimulation of cyclic AMP synthesis (500 pM). This discrepancy may indicate that only a small fraction of specific vasopressin receptors is necessary to produce maximum stimulation of cyclic AMP synthesis in mononuclear phagocytes. Thus, it is possible that the already described "receptor-reserve phenomenon" for vasopressin is operative not only in the kidney but also in the mononuclear phagocytes ofthe circulating blood. A significant increase was seen in binding of the hormone to peripheral blood cells from patients with the hereditary type of diabetes insipidus when compared with patients with diabetes mellitus or with normal individuals. This increase in binding may result in the increased tissue sensitivity to AVP observed in patients with the hypothalamic dysfunction syndrome (27) . This increase in binding is not due to changes in membrane properties of the cells in these patients, as the binding of insulin was unchanged in comparison with peripheral cells from normal individuals. The data indicate that the ADH receptor on human mononuclear phagocytes is distinct from other hormone receptors. It will be interesting to apply the method described here to peripheral blood cells of various types of diabetes insipidus and to investigate its use as a potential diagnostic tool.
